Catherine Mageeney is seeking a “kill shot” in bacterial pathogens

Catherine Mageeney in front of Sandia’s Thunderbird logo.

Catherine Mageeney, a senior member of Sandia’s technical staff in bioengineering and biotechnology, has expertise in phage biology and genetics with broad applications and implications for scientific research. Phages, or viruses that infect bacteria, are the most numerous and diverse biological-organism in Earth’s biosphere. With approximately 1031 existing phages to be identified and studied, there is no shortage to identify, characterize, sequence, and analyze.

Mageeney’s phage research bridges several related areas of bioscience, including not only infectious diseases, but also climate study, biomanufacturing and bioenergy. She sees the plethora of phages “as a toolkit for solving complex biological problems by delivering useful genetic material to alter or kill unwanted bacterial pathogens.”

Mageeney has spent years in this field of discovery science since being introduced as a Cabrini College undergraduate, and she currently leads a team of undergraduate students in the Applied Bioscience Lab at Sandia/California.


Sandia researcher linked to work


Sponsored by

Image of CMYK_Color-Seal_Green-Mark_SC_Vertical
Image of LDRD_Icon-01

Associated Publications

Mageeney, C., Trubl, G., & Williams, K. (2022). Improved Mobilome Delineation in Fragmented Genomes. Frontiers in Bioinformatics. 2.

Stefan, M., Light, Y., Schwedler, J., McIlroy, P., Courtney, C., Saada, E., Thatcher, C., Phillips, A., Bourguet, F., Mageeney, C., McCloy, S., Collette, N., Negrete, O., Schoeniger, J., Weilhammer, D., & Harmon, B. (2021). Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies. mAbs. 13.

Mageeney C.M., Sinha A., Mosesso R.A., Medlin D.L., Lau B.Y., Rokes A.B., Lane T.W., Branda S.S., & Williams K.P. (2020). Computational Basis for On-Demand Production of Diversified Therapeutic Phage Cocktails. mSystems. Aug 11;5(4):e00659-20.


Relevant Content

2021 R&D 100 Award for Analytical/Test Category, Potent and Effective Synthetic SARS-CoV-2 Neutralizing Nanobodies

2021 National Lab Accelerator Pitch Event, Platform for Discovery, Design, and Engineering of Antibody Therapeutics for Emerging Viruses